We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > clinical application

News List

Novartis’ CTL019 Applied for Clinical Trial in China to Officially Enter the Chinese Market PharmaSources/Xiaoyaowan
August 27, 2019
Novartis develops the world’s first CAR T-cell therapy CTL019. And now the drug has been accepted by the CDE.
Update on Priority Review by CDE: Acceptance of First CAR-T Therapy Clinical Application cccmhpie
February 02, 2018
On December 11, 2017, the first CAR-T project clinical application in China (CXSL1700201) filed by Nanjing Legend Biotechnology Co., Ltd. (hereinafter referred to as Nanjing Legend) was formally undertaken and accepted by the CDE
PD-1 and its clinical application: A 20 year journey after discovery of the complete human PD-1 gene sciencedirect
November 07, 2017
Summarize the discovery of the human PD-1 gene and its associated pathway.Review the current use of PD-1 immune checkpoint inhibition in treating cancers.Emphasize challenges to PD-1 immunotherapy and the need for greater understanding of how PD-1 regulat